AIPher
Latest round
- Angel
Last raised
- Sep 2026
Total raised
- $15M
Investors
- 2
About AIPher
, trading as AlPher, is an AI-native drug developer focusing on AI-driven innovative drug development. It collaborates with pharmaceutical companies, biotech companies, and research institutions through a co-development model, covering the entire process from target discovery, molecular design, and experimental validation to candidate drug optimization. The company provides AI-enabled drug discovery and co-development services for pharmaceutical and biotechnology partners. The company generates revenue through co-development partnerships, milestone payments, licensing agreements, and downstream revenue-sharing arrangements related to drug development programs.drug development intelligent engine PharmAgents.
Who invested in AIPher
2 investors across 1 round
See all investors in AIPher
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Sep 3, 2026
Amount
$15M
Investors
Questions about AIPher
Who invested in AIPher?
AIPher has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AIPher raised?
AIPher has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AIPher last raise money?
AIPher's most recent round on record is a Angel, in Sep 2026.
What does AIPher do?
, trading as AlPher, is an AI-native drug developer focusing on AI-driven innovative drug development.
Where is AIPher headquartered?
AIPher is headquartered in Beijing, China.
Which VCs invest in companies like AIPher?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back pharmaceuticals companies at AIPher's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Angel
Raising like AIPher? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.